Today Monday , 6 April 2026
Subscribe
Subscribe
Home Economy Neurocrine nears $2.5bn-plus deal for biotech behind obesity disorder treatment
EconomyGlobal Economy

Neurocrine nears $2.5bn-plus deal for biotech behind obesity disorder treatment

ByApril 6, 20261 Mins read0 Views
Share
Share
Soleno Therapeutics makes first commercialised drug for extreme hunger caused by Prader-Willi syndrome
Share
Previous post AI dolls offer companionship to the elderly

Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Articles

Bank of England divided over how to tackle energy-induced inflation

ByApril 6, 2026

EU warns capitals against turning energy crunch into fiscal crisis

ByApril 6, 2026

Trump family-linked investment group backs spa company offering medical screening

ByApril 6, 2026

Why this oil shock is different

ByApril 6, 2026
© Copyright 2024 Jellywp. All rights reserved powered by Jellywp.com